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Background: The complement component C1q triggers activation of the classical immune pathway and can bind
to adiponectin (APN). Recently, some studies have been reported that serum C1q-APN/total APN ratio correlates
with atherosclerosis and coronary artery disease (CAD). We assessed the relationships between C1q related variables
and the severity of CAD, and investigated the localization of the C1q–APN complex.
Methods: The sample included 153 subjects comprising healthy controls and patients with subclinical or overt
CAD. We measured the serum concentrations of C1q, total APN, and high-molecular weight (HMW)-APN, and the
amount of C1q–APN complex. We identified the sites of C1q–APN complex deposition in various adipose tissues
and blood vessels.
Results: Serum concentrations of C1q and HMW-APN and the C1q/HMW-APN ratio were independently associated
with the severity of coronary stenosis. The amount of C1q–APN complex was significantly higher in patients with
CAD compared with controls. C1q and APN co-localized in perivascular areas of subcutaneous, visceral, and pericardial
fat tissues, and the internal mammary artery of patients with severe CAD.
Conclusions: Serum C1q concentration and the C1q/HMW-APN ratio were independent markers of coronary artery
stenosis. The amount of C1q–APN complex was significantly greater in serum from CAD patients. C1q and APN
co-localized to perivascular areas in adipose tissue and blood vessels. The association between the increased amount
of the C1q–APN complex and CAD should be investigated further.
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The incidence of cardiovascular diseases has increased
markedly in recent years, and atherosclerotic coronary
artery disease (CAD) is now the most common cause of
death in the world. The process of atherosclerosis is me-
diated by chronic inflammation in which dyslipidemia,
hypertension, and diabetes play important pathogenic
roles [1,2]. Considering the potentially fatal consequences
of CAD, it is important to find biomarkers that can pre-
dict CAD early and precisely. To date, a number of adipo-
kines and inflammatory cytokines have been investigated
in the search for reliable predictors of CAD [3,4].
Adiponectin (APN) is a well-known adipokine secreted
almost exclusively by adipocytes and circulates at a high
concentration [5]. It has beneficial effects on insulin sen-
sitivity and glucose homeostasis [6,7]. APN also inhibits
inflammation and plays a role in the prevention of
atherosclerosis. Thus, it is considered to be a protective
adipokine and is therefore a potential therapeutic agent
to prevent or treat atherosclerosis [8,9]. APN has a adhe-
sive property and exists as large homo-oligomers in tri-
mer, hexamer, and high-molecular weight (HMW) forms
[10]. Some studies have suggested that the HMW form
(HMW-APN) is the most biologically active form [11]
and is a more accurate, independent risk factor for CAD
than is the total APN amount or concentration [12,13].
Complement is a major system involved in host innate
immunity [14]. Complement 1q (C1q), a subcomponent
of complement C1, plays a key role in triggering activa-
tion of the classical pathway by recognition of immune
complexes [15]. Like APN, C1q is abundant in the circu-
lation and is structurally similar to APN; both have a
collagen-like domain and a globular heads domain [16].
C1q is important in the immune response involving
complement activation, but little is known about its role
in chronic, low-grade systemic inflammation, which
plays an important role in metabolic diseases such as
atherosclerosis. One study has demonstrated that re-
combinant and native human APN binds to purified
C1q under physiological conditions [17]. Recent studies
have reported that the C1q–APN protein complex exists
in human blood [18,19] and that the serum C1q–APN/
total APN ratio may serve as a biomarker of CAD [20].
However, the clinical significance and physiological func-
tion of the C1q–APN complex and the tissue sites of
C1q–APN complex deposition are not well known.
We measured the amount of serum APN parameters in-
cluding C1q, total APN, HMW-APN, and C1q–APN
complex to determine whether any of these variables cor-
relates with the severity of coronary artery stenosis and
could thus serve as a biomarker of CAD. We identified
the deposition sites of C1q and APN in various adipose
tissues and blood vessel to provide a better understanding
of the C1q–APN complex in CAD patients.Methods
Study subjects
A total of 153 subjects were enrolled in this study. This
included 113 asymptomatic patients who had undergone
a cardiac evaluation with 64-slice multidetector com-
puted tomography (MDCT) either as a health check or
for cardiac evaluation of high-risk patients with predia-
betes or drug-naïve patients with type 2 diabetes at the
Seoul National University Bundang Hospital [SNUBH]
from March 2005 to May 2010.
The other 40 subjects were symptomatic patients with
coronary artery stenosis ≥50% in three major coronary
arteries. Elective coronary artery bypass surgery was
performed and samples of whole adipose tissue (sub-
cutaneous, visceral (preperitoneal), and/or pericardial
fat), internal mammary artery, and blood were obtained
as a part of a study to identify candidate biomarkers of
atherosclerosis.
We identified their risk factors from medical history,
demographics, baseline clinical profile, and concomitant
medications. This study was conducted according to the
Declaration of Helsinki and was approved by ethics
committees of SNUBH (SNUBH IRB#B-1203/147-006,
#A111218-CP02) and all subjects provided their written
informed consent.
Measurement of anthropometric and biochemical
parameters
Body weight, height, and blood pressure were measured at
enrollment in the study. Body mass index was calculated
as the weight in kilograms divided by the square of
the height in meters (kg/m2). Serum concentrations of
total cholesterol, triglycerides, high-density lipoprotein-
cholesterol, low-density lipoprotein (LDL)-cholesterol,
aspartate aminotransferase, alanine aminotransferase,
creatinine, glycated hemoglobin (HbA1c), high-sensitivity
C-reactive protein (hs-CRP), and plasma glucose were
measured after a ≥12-hour fast. We defined diabetes
mellitus as a fasting plasma glucose concentration
of ≥126 mg/dL, an HbA1c level ≥6.5%, or taking anti-
diabetic medicine. Hypertension was defined as systolic
blood pressure >140 mmHg, or diastolic blood pres-
sure >90 mmHg, or taking antihypertensive medicine.
Dyslipidemia was defined as an LDL-C concentration
of ≥130 mg/dL, or hypertriglyceridemia (triglyceride
concentration ≥200 mg/dL), or taking lipid-lowering
medicine. Serum C1q concentration was measured
using an enzyme-linked immunosorbent assay (ELISA)
kit (HK356, Hycult Biotech, Uden, The Netherlands)
using samples that had been frozen at −80°C until ana-
lyzed. ELISA kits were used to measure serum total
APN concentration (EZHADP-61 K, Millipore, Billerica,
MA, USA) and HMW-APN (EZHMWA-64 K, Millipore)
in the same samples.
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CAD was detected using 64-slice MDCT during a rou-
tine health examination. Subjects with a heart rate >70
beats per min received 10–30 mg of intravenous esmolol
(Jeil Pharm, Seoul, Korea) before MDCT imaging. CT
angiography was performed with a 64-slice MDCT scan-
ner (Brilliance 64, Philips Medical Systems, Best, The
Netherlands) using the standard scanning protocol de-
scribed previously [21].
Definition of coronary artery stenosis
Coronary artery stenosis was identified as percent of
luminal narrowing of at least 1 major coronary artery
and was evaluated with MDCT or coronary angiography.
Coronary artery stenosis was categorized into three clas-
sifications: normal (any coronary artery stenosis <25%),
mild to moderate (any coronary artery stenosis ≥25%),
and severe (three coronary artery stenosis ≥50%; coro-
nary artery bypass surgery). The presence of CAD was
defined as any coronary artery stenosis ≥50% regardless
of number of involved coronary artery.
Blood and tissue samples
Serum was obtained from peripheral blood at the time
of patient enrollment. Fat tissues from subcutaneous,
visceral, and pericardial areas, and samples of the in-
ternal mammary artery were obtained from 40 patients
during coronary artery bypass surgery and were irrigated
with saline. All of the samples were stored at −80°C until
analyzed.
Immunoblotting assay to detect the C1q–APN complex
Human serum was mixed with C1q antibody (SC-53544,
Santa Cruz Biotechnology, Dallas, TX, USA) in 1× kinase
buffer (20 mM HEPES pH 7.4, 5 mM MgCl2, 1 mM
dithiothreitol) and agitated overnight at 4°C. Protein G
(17-0618-01, GE Healthcare, Buckinghamshire, UK) was
added to the mixture, and the mixture was rotated for 4 h
at 4°C. After three washes, the C1q-immunocomplexes
were subjected to sodium dodecyl sulfate-polyacrylamide
gel electrophoresis and western blotting using anti-APN
antibody (ab18851, Abcam, Cambridge, UK).
Histological analysis
Deparaffinized adipose tissue sections and blood vessels
were fixed in 4% paraformaldehyde in phosphate-buffered
saline. The sections of fat tissues and vessels were stained
with hematoxylin–eosin. Immunostaining was performed
overnight at 4°C with mouse anti-C1q (ab71089, Abcam,)
or with rabbit anti-APN (NB100-65810, Novus Biologicals,
Littleton, CO, USA) antibodies. The sections were then
washed and incubated in Alexa Fluor 488 goat anti-rabbit
IgG (Moleaulr Probes, Eugene, OR) and Alexa Fluor 594
goat anti-mouse IgG (Molecular Probes, Eugene, OR) asthe secondary antibody for 1 h at 37°C. The slides were
examined under a Zeiss Axio Imager A1 fluorescent
microscope (Carl Zeiss, Cambridge, UK).
Statistical analysis
All values are expressed as mean and standard deviation
(SD) or number (percent). Clinical parameters that were
not normally distributed were log-transformed to reduce
the skewness; we present the results as the anti-logarithm
for ease of interpretation. Differences in parameters bet-
ween groups were analyzed using χ2-test, Student’s t-test,
or one-way analysis of variance (ANOVA). When sig-
nificantly different values were observed in an ANOVA,
Bonferroni post hoc analysis was applied to identify the
significantly different values. Simple and multivariate lo-
gistic regression analysis was used to determine the asso-
ciations between parameters and CAD. A p-value <0.05
was considered significant. All analyses were performed
using SPSS 17.0 for Windows.
Results
Baseline characteristics of subjects
The characteristics of the study subjects are summarized
in Table 1. Serum C1q and HMW-APN concentrations
were significantly lower in patients with severe coronary
artery stenosis compared with those with no stenosis or
mild to moderate stenosis. There was a trend toward a
stepwise decrease in these concentrations with severity
of stenosis. However, serum total APN concentration
did not differ significantly between the groups. The C1q/
HMW-APN ratio was significantly higher in patients
with severe stenosis compared with those with no sten-
osis or with mild to moderate stenosis (Table 1).
Men had significantly lower serum concentrations of
both total APN and HMW-APN than women: 5.40 ± 3.71
and 9.51 ± 4.17 μg/mL (P <0.001) for total APN and
2.91 ± 2.33 and 5.34 ± 3.75 μg/mL for HMW-APN
(P <0.001), respectively. Serum C1q concentration did not
differ significantly between men and women (5.19 ± 1.50
and 5.32 ± 1.64 μg/mL, respectively; P = 0.656).
Simple and multivariate logistic regression analyses of
the associations between APN parameters and CAD
Logistic regression analysis was performed to evaluate
the relationship between CAD and various APN parame-
ters (Table 2). Simple logistic regression analysis showed
that the presence of CAD correlated significantly with
the concentrations of C1q, HMW-APN, and the C1q/
HMW-APN ratio. Following adjustment for age and sex,
the associations between CAD and the concentration of
C1q, HMW-APN, and the C1q/HMW-APN ratio were
significant. After adjusting for age, sex, body mass index,
diabetes mellitus, hypertension, and dyslipidemia, the
concentrations of C1q total APN, HMW-APN, and the
Table 1 Baseline characteristics of subjects according to coronary artery stenosis
Normal (n = 72) Mild to moderate (n = 41) Severe (n = 40) P value
Age (years) 56.4 ± 7.8a 57.4 ± 11.0a 67.0 ± 10.3b <0.001
Sex (male/female) 36/36a 32/9b 31/9b 0.002
Body mass index (kg/m2) 24.9 ± 2.7a,b 25.9 ± 2.5a 24.1 ± 3.4b 0.025
Systolic blood pressure (mmHg) 128.1 ± 13.7 126.5 ± 13.4 125.1 ± 17.7 0.596
Diastolic blood pressure (mmHg) 77.2 ± 10.1a 78.7 ± 9.3a 70.7 ± 10.3b 0.001
Fasting blood glucose (mg/dL) 114.4 ± 32.3a 129.9 ± 42.4a,b 156.4 ± 70.0b 0.001
HbA1c (%) 6.3 ± 1.1a 6.9 ± 1.6a,b 7.0 ± 1.5b 0.018
Total cholesterol (mg/dL) 215.3 ± 31.2a 209.3 ± 39.7a 171.0 ± 49.4b <0.001
Triglycerides (mg/dL) 172.7 ± 99.6 206.2 ± 201.3 147.5 ± 110.9 0.205
HDL-cholesterol (mg/dL) 52.8 ± 12.0a 48.7 ± 12.5a,b 43.4 ± 10.2b <0.001
LDL-cholesterol (mg/dL) 118.7 ± 27.5 120.2 ± 36.5 101.4 ± 37.9 0.039
Aspartate aminotransferase (IU/L) 24.6 ± 11.3a 26.2 ± 8.3a 37.7 ± 22.4b <0.001
Alanine aminotransferase (IU/L) 30.3 ± 21.2 35.5 ± 22.8 29.2 ± 18.3 0.225
Creatinine (mg/dL) 1.0 ± 0.2 1.1 ± 0.2 1.2 ± 0.7 0.265
hs-CRP (mg/dL) 0.1 ± 0.1a 0.6 ± 2.2a,b 2.0 ± 4.5b <0.001
Diabetes mellitus (%) 38.9 48.8 62.5 0.056
Sulfonyl ureas/biguanides/thiazolidinediones/dipeptidyl
peptidase-4 inhibitors/insulin (n)
2/6/1/1/0 3/7/2/2/1 8/8/4/2/2 0.912
Hypertension (%) 30.6a 61.0b 75.0b <0.001
Calcium channel blockers/angiotensin receptor blockers/
angiotensin-converting-enzyme inhibitor/β-blockers/diuretics (n)
6/5/1/1/1 10/12/2/3/5 12/13/6/4/4 0.934
Dyslipidemia (%) 51.4 63.4 72.5 0.081
Statins/fibrates/ezetimibe (n) 18/3/0 20/4/0 25/5/1 0.821
C1q (μg/ml) 5.77 ± 1.68a 5.38 ± 1.34a 4.13 ± 0.75b <0.001
Total APN (μg/ml) 7.74 ± 4.59 5.89 ± 4.23 6.51 ± 3.95 0.097
HMW-APN (μg/ml) 4.91 ± 3.70a 3.19 ± 2.20a 1.51 ± 0.50b <0.001
C1q/Total APN ratio 1.15 ± 0.98 1.67 ± 1.52 1.00 ± 0.85 0.48
C1q/HMW-APN ratio 2.46 ± 2.52a 2.77 ± 2.33a,b 3.08 ± 1.31b 0.047
Data are presented as the mean ± SD. a,bValues with the same letter did not differ significantly by Bonferroni post hoc analysis or χ2-tests. Normal, any coronary
artery stenosis <25%; mild to moderate, any coronary artery stenosis ≥25%; severe, three coronary artery stenosis ≥50% (coronary artery bypass surgery). HbA1c,
glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; APN, adiponectin; HMW-APN,
high-molecular weight APN.
Table 2 Simple and multivariate logistic regression analysis of the associations between APN parameters and CAD
Unadjusted Age and sex adjusted Multivariable adjusted
OR CI p-value OR CI p-value OR CI p-value
C1q 0.02 0.003 - 0.090 <0.001 0.02 0.004 – 0.152 <0.001 0.01 0.001 – 0.091 <0.001
Total APN 0.95 0.874 – 1.036 0.252 0.93 0.832 – 1.037 0.191 0.88 0.770 – 0.996 0.044
HMW-APN 0.35 0.210 – 0.581 <0.001 0.31 0.165 – 0.573 <0.001 0.25 0.121 – 0.517 <0.001
C1q/total APN 0.84 0.537 – 1.327 0.464 0.89 0.517 – 1.546 0.689 0.98 0.521 – 1.826 0.937
C1q/HMW-APN 1.77 1.143 – 2.733 0.010 1.99 1.151 – 3.430 0.014 2.09 1.122– 3.907 0.020
OR, odds ratio; CI, confidence interval; APN, adiponectin; HMW-APN, high-molecular weight APN.
Multivariable analysis adjusted for age, sex, body mass index, diabetes, hypertension, and dyslipidemia.
Bold means significant value.
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with CAD (odds ratio, OR 0.01 [confidence interval,
CI 0.001 – 0.091]; OR 0.88 [CI 0.77 0– 0.996]; OR 0.25
[CI 0.121 – 0.517]; and OR 2.09 [CI 1.122 – 3.907],
respectively).
Detection of C1q-APN complex in human serum
To confirm whether C1q and APN form complexes in
human serum, we performed immunoprecipitation and
an immunoblotting assay. Serum samples from normal
controls without CAD (n = 8) and from patients with
CAD (n = 8) were subjected to immunoprecipitation with
antibody against C1q, followed by immunoblotting with
antibody against APN. APN was detected in C1q immu-
noprecipitates (Figure 1A). The serum C1q–APN complex
was detected, and the relative amount of serum C1q–
APN complex in the serum was about twofold higher in
patients with CAD compared with the controls (P = 0.026)
(Figure 1B).
Immunofluorescence of C1q and APN in adipose tissue
and blood vessels
We selected samples of adipose tissue (visceral, pericar-
dial, and subcutaneous fat) and the internal mammary
artery taken during coronary artery bypass surgery from
four patients with CAD. The samples were stained for
C1q and total APN using immunofluorescent antibodies.
Positive staining for C1q and total APN by immuno-
fluorescence was shown along the perivascular areas inFigure 1 Detection of the C1q–APN complex in human serum. A, The am
of the serum from 16 subjects. B, The relative expression of the C1q–APN c
normal controls (CAD(−)) (P = 0.026).all fat tissues and in the intimal–medial layer of blood
vessels. C1q and APN were almost completely co-
localized in the same areas. Because the results were
similar among 4 subjects, we showed the results of 1
subject, representatively (Figure 2).
Discussion
The major findings of the present study are as follows.
First, serum C1q concentration was significantly lower
and the serum C1q/HMW-APN ratio significantly higher
in subjects with severe coronary artery stenosis compared
with subjects with no stenosis or mild to moderate sten-
osis. By contrast, APN concentration did not differ ac-
cording to the presence or absence of stenosis. Second,
the amount of the C1q–APN complex in serum was sig-
nificantly higher in subjects with CAD than in subjects
without CAD. Third, the C1q and APN co-localized to
the perivascular areas of adipose tissues and intimal–
medial layer of blood vessels of CAD patients.
C1q is the first component of the serum complement
system. It comprises six globular “heads” linked via six
collagen-like “stalks” to a fibril-like central region and
possesses significant homology to APN [16]. The tra-
ditionally accepted role of C1q is the recognition of im-
mune complexes and activation of the classical pathway.
Binding of Fc regions of immunoglobulin to the globular
head portion of C1q induces further activation of the cas-
cade of proteins comprising the classical pathway [22].
C1q is produced by and deposits around macrophagesount of C1q–APN complex was measured by coimmunoprecipitation
omplex was 1.8-times higher in patients with CAD (CAD(+)) than in
Figure 2 Co-localization of C1q and APN deposited in adipose tissue and blood vessels (×100). Positive staining of C1q (red) and APN (green) is
shown along the perivascular areas of fat tissues and intimal–medial layer of the blood vessel. C1q and APN co-localized almost completely in
the same areas. H&E, hematoxylin and eosin.
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ever, the role of C1q is not restricted to recognition of im-
mune complexes or other molecules. Nontraditional roles
of C1q are rapidly emerging and include autoimmune dis-
eases and carcinogenesis [24], but little is known about its
possible role in chronic metabolic diseases such as athero-
sclerosis, obesity, and diabetes.
C1q has recently been suggested to play a role in
atherosclerosis when complexed with APN. Previously, it
has reported that the C1q–APN complex exists in the
blood and has suggested that the C1q–APN/total APN
ratio is a useful predictive marker of the metabolic syn-
drome and CAD in Japanese people [18,20,25]. A high
serum C1q–APN/total APN ratio was associated with
CAD prevalence, independent of other CAD risk factors
in a previous study [20]. We measured the serum con-
centrations of C1q, total APN, and HMW-APN, and
their associations with the severity of CAD. Previous
studies have reported nonsignificant correlations bet-
ween C1q, HMW-APN, and atherosclerotic disease
[20,25]. However, in contrast to the previous results, we
found that the serum concentrations of C1q and HMW-
APN were independently associated with CAD and de-
creased significantly with increasing severity of coronary
artery stenosis. The total APN concentration and the
C1q/total APN ratio were not associated with the pre-
sence or severity of CAD. We could not measure theabsolute concentration of the C1q–APN complex in the
blood because no commercial ELISA kit is available for
the direct measurement of the complex. Instead, we
measured the quantity of C1q–APN complex in coim-
munoprecipitation experiments. The amount of C1q–
APN complex was significantly higher in the blood of
patients with CAD than in the controls with no CAD.
Our result is concordant with the other study that serum
C1q-APN levels were significantly higher in the acute
coronary syndrome than in the normal coronary group
[26]. Recently, the protein family C1q/TNF-related pro-
tein (CTRP) has been discovered as adiponectin paralog.
Some CTRP family members have metabolic regulatory
function in glucose and/or fat homeostasis [27]. CTRP-3
is an anti-inflammatory adipokine and serum CTRP-3
concentrations are significantly decreased in patients
with acute coronary syndrome [28]. Serum CTRP-1 and
CTRP-3 levels were positively associated with athero-
sclerosis [29,30]. These results suggest that APN para-
meters including C1q, C1q-APN complex and CTRPs
might be important in the regulation of atherosclerosis
and development of acute coronary syndrome.
Interestingly, we confirmed the deposition of the C1q
and APN in human white adipose tissues and blood ves-
sels. Immunofluorescence showed that C1q and APN
co-localized in the perivascular areas of fat tissues and in
the intimal–medial area of the artery. APN is known to
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the vascular intima. APN is detected in the walls of in-
jured arteries and in atherosclerotic lesions [31]. Our
study is the first to show the co-localization of C1q and
APN in human tissues. However, it remains unclear
which forms of circulating APN forms protein complex
with C1q. The precise physiological role of the complex
is also unknown, but we speculate that APN may play a
protective role in the C1q-induced activation of the
complement pathway, which is known as a cause of vas-
cular damage in autoimmune disease or other types of
inflammation that contribute to systemic atherosclerosis.
APN is thought to prevent inflammation and to play a
beneficial role in preventing atherosclerosis and metabolic
syndrome [32,33]. One study reported that adiponectin
protects against activation of C1q-induced inflammation
in injured tissues of mice [34], which is similar evidence as
our result of C1q-APN co-localization in perivascular tis-
sues. Further research is needed to clarify the role of the
C1q–APN complex in protecting against the development
of atherosclerosis in humans.
The present study has several limitations. First, it was
a cross-sectional study, making it difficult to interpret
whether there is a causal relationship between the
markers measured in this study and CAD. Further pro-
spective studies are needed to confirm this relationship.
Second, we could not directly measure the serum con-
centration and tissue deposit of C1q-APN complex be-
cause of the lack of a commercially available method.
Third, the number of serum and tissue samples used in
the tests for detection of C1q and APN was small. Al-
though we repeated the tests, there could be a selection
bias. Forth, we could not get tissue and blood vessel
samples of normal healthy control.
Conclusion
In conclusion, the present study demonstrated that serum
C1q concentration and the C1q/HMW-APN ratio were
independent markers of coronary artery stenosis. The co-
localization of the C1q and APN was observed in the peri-
vascular areas of fat tissues and in the intimal–medial area
of the internal mammary artery in conjunction with a
higher serum amount of the C1q–APN complex in pa-
tients with CAD. These results suggest that the C1q–APN
complex may play a role in the development of athero-
sclerosis. Further human studies are needed to clarify
whether the C1q–APN complex is a potential target for
new treatments to protect against atherosclerosis.
Abbreviations
CAD: Coronary artery disease; APN: Adiponectin; HMW: High-molecular
weight; C1q: Complement 1q; MDCT: Multidetector computed tomography;
LDL: Low-density lipoprotein; HbA1c: Glycated hemoglobin; hs-CRP: High-
sensitivity C-reactive protein; ELISA: Enzyme-linked immunosorbent assay;
SD: Standard deviation; ANOVA: Analysis of variance; OR: Odds ratio;
CI: Confidence interval; CTRP: C1q/TNF-related protein.Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ESH analyzed the data and wrote the manuscript. CL contributed materials.
HYC performed the experiments. EJK, KMK, JHM, SL, KSP, and HCJ contributed
to the discussion and reviewed the manuscript. SHC conceived and designed
the experiments. All authors read and approved the final manuscript.
Acknowledgements
This study was supported by the grant of the Korean Health Technology R&D
Project, Ministry of Health & Welfare, Republic of Korea (grant number HI14C0074).
This work was supported by a grant (E.S.H., 2013) from the Korean Diabetes
Association.
Author details
1Department of Internal Medicine, Seoul National University College of
Medicine and Seoul National University Bundang Hospital, 300, Gumi-dong,
Bundang-gu, Seongnam 463-707, South Korea. 2Department of Internal
Medicine, Seoul National University College of Medicine, Seoul, South Korea.
3Department of Thoracic and Cardiovascular Surgery, Seoul National
University College of Medicine and Seoul National University Bundang
Hospital, Seongnam, South Korea.
Received: 23 January 2015 Accepted: 9 April 2015
References
1. Williams KJ, Tabas I. The response-to-retention hypothesis of early
atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15(5):551–61.
2. Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med.
1999;340(2):115–26.
3. Syed Ikmal SI, Zaman Huri H, Vethakkan SR, Wan Ahmad WA. Potential
biomarkers of insulin resistance and atherosclerosis in type 2 diabetes
mellitus patients with coronary artery disease. Int J Endocrinol.
2013;2013:698567.
4. Choi SH, Hong ES, Lim S. Clinical implications of adipocytokines and newly
emerging metabolic factors with relation to insulin resistance and
cardiovascular health. Front Endocrinol (Lausanne). 2013;4:97.
5. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al.
Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.
Biochem Biophys Res Commun. 1999;257(1):79–83.
6. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene
dysregulated in obesity. J Biol Chem. 1996;271(18):10697–703.
7. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al.
Plasma concentrations of a novel, adipose-specific protein, adiponectin, in
type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20(6):1595–9.
8. Motoshima H, Wu X, Mahadev K, Goldstein BJ. Adiponectin suppresses
proliferation and superoxide generation and enhances eNOS activity in
endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun.
2004;315(2):264–71.
9. Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A. Vascular effects of adiponectin:
molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond).
2008;114(5):361–74.
10. Schraw T, Wang ZV, Halberg N, Hawkins M, Scherer PE. Plasma adiponectin
complexes have distinct biochemical characteristics. Endocrinology.
2008;149(5):2270–82.
11. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H.
Measurement of the high-molecular weight form of adiponectin in plasma
is useful for the prediction of insulin resistance and metabolic syndrome.
Diabetes Care. 2006;29(6):1357–62.
12. Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H. Serum
concentrations of adiponectin and risk of type 2 diabetes mellitus and
coronary heart disease in apparently healthy middle-aged men: results from
the 18-year follow-up of a large cohort from southern Germany. J Am Coll
Cardiol. 2006;48(7):1369–77.
13. Lim S, Koo BK, Cho SW, Kihara S, Funahashi T, Cho YM, et al. Association of
adiponectin and resistin with cardiovascular events in Korean patients with
type 2 diabetes: the Korean atherosclerosis study (KAS): a 42-month
prospective study. Atherosclerosis. 2008;196(1):398–404.
Hong et al. Cardiovascular Diabetology  (2015) 14:50 Page 8 of 814. Reid KB. Activation and control of the complement system. Essays Biochem.
1986;22:27–68.
15. Schumaker VN, Zavodszky P, Poon PH. Activation of the first component of
complement. Annu Rev Immunol. 1987;5:21–42.
16. Arlaud GJ, Gaboriaud C, Thielens NM, Rossi V, Bersch B, Hernandez JF, et al.
Structural biology of C1: dissection of a complex molecular machinery.
Immunol Rev. 2001;180:136–45.
17. Peake PW, Shen Y, Walther A, Charlesworth JA. Adiponectin binds C1q and
activates the classical pathway of complement. Biochem Biophys Res
Commun. 2008;367(3):560–5.
18. Nakatsuji H, Kobayashi H, Kishida K, Nakagawa T, Takahashi S, Tanaka H,
et al. Binding of adiponectin and C1q in human serum, and clinical
significance of the measurement of C1q-adiponectin / total adiponectin
ratio. Metabolism. 2013;62(1):109–20.
19. Kishida K, Kishida N, Arima M, Nakatsuji H, Kobayashi H, Funahashi T, et al.
Serum C1q- binding adiponectin in maintenance hemodialysis patients.
BMC Nephrol. 2013;14:50.
20. Hirata A, Kishida K, Nakatsuji H, Kobayashi H, Funahashi T, Shimomura I.
High serum C1q-adiponectin/total adiponectin ratio correlates with
coronary artery disease in Japanese type 2 diabetics. Metabolism.
2013;62(4):578–85.
21. Choi EK, Choi SI, Rivera JJ, Nasir K, Chang SA, Chun EJ, et al. Coronary
computed tomography angiography as a screening tool for the detection
of occult coronary artery disease in asymptomatic individuals. J Am Coll
Cardiol. 2008;52(5):357–65.
22. Siegert CE, Kazatchkine MD, Sjoholm A, Wurzner R, Loos M, Daha MR.
Autoantibodies against C1q: view on clinical relevance and pathogenic role.
Clin Exp Immunol. 1999;116(1):4–8.
23. Lu JH, Teh BK, Wang L, Wang YN, Tan YS, Lai MC, et al. The classical and
regulatory functions of C1q in immunity and autoimmunity. Cell Mol
Immunol. 2008;5(1):9–21.
24. Ghebrehiwet B, Hosszu KK, Valentino A, Peerschke EI. The C1q family of
proteins: insights into the emerging non-traditional functions. Front
Immunol. 2012;3:52.
25. Hirata A, Kishida K, Kobayashi H, Nakatsuji H, Funahashi T, Shimomura I.
Correlation between serum C1q-adiponectin/total adiponectin ratio and
polyvascular lesions detected by vascular ultrasonography in Japanese type
2 diabetics. Metabolism. 2013;62(3):376–85.
26. Kishida K, Nakagawa Y, Kobayashi H, Mazaki T, Yokoi H, Yanagi K, et al. High
serum C1q-binding adiponectin levels in male patients with acute coronary
syndrome. Cardiovasc Diabetol. 2014;13:9.
27. Seldin MM, Tan SY, Wong GW. Metabolic function of the CTRP family of
hormones. Rev Endocr Metab Disord. 2014;15(2):111–23.
28. Choi KM, Hwang SY, Hong HC, Choi HY, Yoo HJ, Youn BS, et al. Implications
of C1q/TNF-related protein-3 (CTRP-3) and progranulin in patients with
acute coronary syndrome and stable angina pectoris. Cardiovasc Diabetol.
2014;13:14.
29. Yuasa D, Ohashi K, Shibata R, Takeshita K, Kikuchi R, Takahashi R, et al.
Association of circulating C1q/TNF-related protein 1 levels with coronary
artery disease in men. PLoS One. 2014;9(6):e99846.
30. Jung CH, Lee MJ, Kang YM, Jang JE, Leem J, Lee YL, et al. Association of serum
C1q/TNF-related protein-9 concentration with arterial stiffness in subjects with
type 2 diabetes. J Clin Endocrinol Metab. 2014;99(12):E2477–2484.
31. Okamoto Y, Arita Y, Nishida M, Muraguchi M, Ouchi N, Takahashi M, et al.
An adipocyte-derived plasma protein, adiponectin, adheres to injured
vascular walls. Horm Metab Res. 2000;32(2):47–50.
32. Duncan BB, Schmidt MI, Pankow JS, Bang H, Couper D, Ballantyne CM, et al.
Adiponectin and the development of type 2 diabetes: the atherosclerosis
risk in communities study. Diabetes. 2004;53(9):2473–8.
33. Luo N, Liu J, Chung BH, Yang Q, Klein RL, Garvey WT, et al. Macrophage
adiponectin expression improves insulin sensitivity and protects against
inflammation and atherosclerosis. Diabetes. 2010;59(4):791–9.
34. Ebina K, Oshima K, Matsuda M, Fukuhara A, Maeda K, Kihara S, et al.
Adenovirus-mediated gene transfer of adiponectin reduces the severity of
collagen-induced arthritis in mice. Biochem Biophys Res Commun.
2009;378(2):186–91.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
